Clinical trials: Treatment-refractory Schizophrenia
Schizophrenia
A Long Term Study of Clozapine in Patients With Treatment-resistant Schizophrenia
Clozapine is an antipsychotic. This open study will evaluate the safety and efficacy of long term treatment of clozapine in patients with treatment-resistant schizophrenia.
- Trial name
- NCT00154258
- Testing
- Clozapine
- Volunteers
- 19 people
- Sponsor
- Novartis
Psychosis, Schizophrenia Disorder
Comparison of Accelerated Intermittent Theta Burst Stimulation vs High Frequency Transcranial Magnetic Stimulation (Hf-rTMS) on Cognitivesymptoms in Treatment-resistant Schizophrenia
This randomized, double-blind, sham-controlled trial compares three brain stimulation approaches-accelerated intermittent theta burst stimulation (aITBS), high-frequency repetitive transcranial magnetic stimulation (HF-rTMS), and…
- Trial name
- DB RCT (NCT07445620)
- Testing
- Accelerated iTBS, High-Frequency rTMS
- Where
- India
- Volunteers
- 90 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia
Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia
To evaluate the efficacy of 10 and 20 mg/day of Lu AF35700 on schizophrenia symptoms in patients with treatment-resistant schizophrenia (TRS)
- Trial name
- DayBreak (NCT02717195)
- Testing
- Risperidone, Olanzapine, Lu AF35700
- Where
- 147 sites in United States, Bulgaria and 12 more
- Volunteers
- 1,098 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia, Hallucinations
Efficacy of tDCS in the Treatment of Resistant Auditory Hallucinations in Schizophrenia
The regions which are assumed to underlie the pathophysiology of schizophrenia, namely hypoactivity at the prefrontal level and pathological hyperactivity of the associative regions of the language located in the left…
- Conditions
- Schizophrenia, Hallucinations, Refractory Schizophrenia
- Trial name
- TDCSHALLU (NCT04352569)
- Testing
- transcranial direct current stimulation
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Centre hospitalier de Ville-Evrard, France
Schizophrenia, Schizoaffective Disorder
Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia
Investigating the effect of non-invasive transcranial current stimulation on auditory hallucinations in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Auditory Hallucinations
- Trial name
- NCT01963676
- Testing
- tDCS
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
Response to Clozapine in Treatment Resistant Schizophrenia: A Longitudinal Magnetic Resonance Spectroscopy Study
The purpose of this study is to investigate the relationship between glutamate and related brain chemicals and treatment response to clozapine in patients with treatment-resistant schizophrenia.
- Trial name
- NCT02714894
- Testing
- Clozapine
- Where
- Canada
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Treatment-resistant Schizophrenia
Neural Biomarkers of Clozapine Response
Clozapine has consistently shown to be a superior drug for psychosis in patients who do not respond to other treatments, but its mechanism of action remains unknown.
- Conditions
- Schizophrenia, Treatment-resistant Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT03076346
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Pittsburgh
Treatment-resistant Schizophrenia
Hippocampus DBS in Treatment-resistant Schizophrenia
The goal of this clinical trial is to assess the efficacy and safety of hippocampus-targeted deep brain stimulation (DBS) in treatment-resistant schizophrenia.
- Trial name
- NCT05694000
- Testing
- On-Stimulation, Off-Stimulation
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shanghai Mental Health Center
Auditory Hallucination, Verbal, Treatment-resistant Schizophrenia
Virtual Reality Therapy for Treatment-resistant Auditory Hallucinations in Schizophrenia
Treatment of verbal hallucinations in schizophrenia is clinically challenging for both the patient and the therapist. For the therapist, one of the main difficulties arises from the impossibility of directly communicating with…
- Trial name
- NCT03148639
- Testing
- Avatar therapy, Treatment-as-usual
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Schizophrenia Spectrum and Other Psychotic Disorders, Treatment-resistant Schizophrenia
Rituximab for Schizophrenia Spectrum Disorder (RITS-PS-2019)
This study evaluates the addition of rituximab to 12 patients diagnosed with treatment resistant schizophrenia spectrum disorder in an open trial.
- Trial name
- NCT03983018
- Testing
- Rituximab
- Where
- Sweden
- Volunteers
- 9 people
- Sponsor
- Region Örebro County
Anti-Psychotic, Management of Manifestations of Psychotic Disorders
Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
Cycle Pharmaceuticals Ltd. (Cycle) is developing an oral tablet formulation of Chlorpromazine Hydrochloride and intends to conduct bioequivalence trials to demonstrate its similarity to the RLD.
- Conditions
- Anti-Psychotic, Management of Manifestations of Psychotic Disorders, Treatment of Schizophrenia, Control Nausea and Vomiting
- Trial name
- NCT02943213
- Testing
- Chlorpromazine Hydrochloride
- Where
- South Africa
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Cycle Pharmaceuticals Ltd.
Refractory Schizophrenia
Repetitive Transcranial Magnetic Stimulation for Refractory Auditory Hallucinations in Schizophrenia
Studies using repetitive transcranial magnetic stimulation (rTMS) as a treatment for refractory auditory hallucinations (AH) in schizophrenia have shown promise.
- Trial name
- NCT01386918
- Testing
- repetitive Transcranial Magnetic Stimulation
- Where
- Canada
- Volunteers
- 144 people
- Sponsor
- Centre for Addiction and Mental Health
Sialorrhea
Clozapine-induced Hypersalivation - Feasibility Trial
A randomised placebo-controlled feasibility study of glycopyrrolate and hyoscine in the treatment of clozapine-induced hypersalivation to assess recruitment and retention rates in a multi-centre trial.
- Trial name
- GOTHIC1 (NCT02613494)
- Testing
- Hyoscine, Glycopyrrolate
- Where
- 2 sites in United Kingdom
- Volunteers
- 29 people
- Sponsor
- Mersey Care NHS Trust
Schizophrenia, Schizo Affective Disorder
Acetazolamide for Treatment Resistant Schizophrenia
This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.
- Trial name
- APTS (NCT04887792)
- Testing
- Acetazolamide
- Where
- 2 sites in United States, India
- Volunteers
- 60 people
- Sponsor
- Vishwajit Nimgaonkar, MD PhD
Schizophrenia or Schizoaffective Disorder
Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm
The objective of this study is to evaluate predictors of response to antipsychotic medication in subjects with schizophrenia. The investigators will evaluate psychopathology,brain MRI, genetics and neuropsychological profile.
- Trial name
- NCT01016145
- Testing
- Antipsychotics
- Where
- Brazil
- Volunteers
- 126 people
- Sponsor
- University of Sao Paulo
Hallucinations, Schizophrenia
Multimodal MRI-guided rTMS to Treat Refractory Hallucinations
The efficacy of neuro-navigated rTMS for patients with schizophrenia suffering from drug-resistant multisensory hallucinations will be tested by the implementation of a double-blind randomized controlled trial (RCT) This study…
- Conditions
- Hallucinations, Schizophrenia, Perceptual Disorders
- Trial name
- MULTIMODHAL (NCT01373866)
- Testing
- MagPro X100 repetitive Transcranial Magnetic Stimulation
- Where
- 2 sites in France
- Volunteers
- 85 people
- Sponsor
- University Hospital, Lille
Schizophrenia
A Study to Evaluate the Safety and Efficacy of Clozapine in Patients With Treatment-resistant Schizophrenia
Clozapine is an antipsychotic. This 24-week study will evaluate the safety and efficacy of clozapine in patients with treatment-resistant schizophrenia. This study is not recruiting in the United States.
- Trial name
- NCT00250575
- Testing
- Clozapine
- Where
- 8 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Novartis
Schizophrenia
Study of m-RESIST, an m-Health Program for Treatment-resistant Schizophrenia
m-RESIST is an m-health intervention program aimed to develop, test and evaluate a tool to allow patients suffering from treatment-resistant schizophrenia to self-manage their condition.
- Trial name
- m-RESIST (NCT03064776)
- Testing
- m-RESIST Patients, m-RESIST Caregivers
- Where
- 3 sites in Hungary, Israel and 1 more
- Volunteers
- 43 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Treatment Resistant Schizophrenia
Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia
Dextromethorphan acts as N-methyl-D-aspartate (NMDA) antagonist. In Treatment resistant schizophrenia(TRS) the efficacy of treatment response by clozapine is only around 40%.
- Trial name
- NCT05944510
- Testing
- Dextromethorphan
- Where
- India
- Volunteers
- 40 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar
Schizophrenia
Effectiveness of Clozapine Versus Olanzapine for Treatment-resistant Schizophrenia
This study will determine the effectiveness of clozapine versus olanzapine in treating people with schizophrenia that has not improved with treatment.
- Trial name
- COES (NCT00169065)
- Testing
- Clozapine, Olanzapine
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Harvard Medical School (HMS and HSDM)